Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
REGN9035 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part A | EXPERIMENTAL | Single ascending dose (SAD) of REGN9035 or matching placebo given by intravenous (IV) administration. |
| Part B | EXPERIMENTAL | Selected doses of REGN5381 or matching placebo given by IV administration followed by selected doses of REGN9035 and/or matching placebo via IV infusion |
| Name | Type | Description |
|---|---|---|
| REGN9035 | DRUG | Part A: Single dose administered by IV infusion on day 1. Part B: Selected doses administered by IV infusion on day 2 or 22. |
| REGN5381 | DRUG | Part B: Selected doses administered by IV infusion on day 1. |
| Placebo | OTHER | Part A: Single dose administered by IV infusion on day1. Part B: Single dose administered by IV infusion on day 1, day 2 and/or day 22. |
Key Inclusion Criteria: 1. Body mass index (BMI) between 18 and 32 kg/m2, inclusive, at the screening visit. 2. Normal or mildly elevated blood pressure as defined in the protocol. Key Exclusion Criteria: 1. History of unexplained syncope or autonomic dysfunction. 2. History of clinically signifi...
REGN9035 is an investigational small molecule being studied in healthy adult volunteers and mildly hypertensive participants. It is currently in Phase 1 clinical development, and the completed trial evaluated its safety, tolerability, pharmacokinetics, and pharmacodynamics in these populations.
REGN9035 is being developed by Regeneron Pharmaceuticals, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol REGN. The company conducted a Phase 1 study of REGN9035 in healthy volunteers and mildly hypertensive participants.
REGN9035 is in Phase 1 clinical development. The single clinical trial for REGN9035, NCT05291546, has been completed. As an investigational drug, REGN9035 has not been approved by regulatory authorities and remains in early-stage clinical testing.
REGN9035 has one completed clinical trial, NCT05291546, titled "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9035 in Healthy Adult Volunteers and Mildly Hypertensive Participants." The trial enrolled 93 participants in Belgium and Germany and was a randomized, double-blind, controlled study.
REGN9035 is the primary identifier for this investigational small molecule. No alternative names have been associated with this drug in the available clinical trial information. It is distinct from other Regeneron pipeline assets and is identified solely by the code REGN9035.